Results of the Galenica Group 2016
The Galenica Group once again reported strong results in 2016. Consolidated net sales grew by 8.6% to CHF 4,118.4 millio…
The Galenica Group once again reported strong results in 2016. Consolidated net sales grew by 8.6% to CHF 4,118.4 millio…
Velphoro® (sucroferric oxyhydroxide) a reçu l'autorisation de mise sur le marché de la Commission européenne pour le con…
Velphoro® (sucroferric oxyhydroxide) has received EU marketing authorisation from the European Commission for the contro…
Velphoro® (Sucroferric Oxyhydroxide) hat von der Europäischen Kommission die Zulassung erhalten zur Kontrolle des Serum-…
. - Velphoro® (PA21) recommended for approval in the European Union for the treatment of hyperphosphatemia in adult Chr…
. - Velphoro® (PA21) in der Europäischen Union zur Zulassung für die Behandlung von Hyperphosphatämie bei dialysepflich…
Galenica increased consolidated net sales by 2.0% to CHF 3,359.4 million in 2013. On a comparable basis, profit before d…
En 2013, le Groupe Galenica a augmenté son chiffre d'affaires net consolidé de 2,0% à CHF 3'359,4 mio. et cela dans un e…
The Galenica Group increased consolidated net sales by 2.0% to CHF 3,359.4 million in 2013, in a market environment char…
Die Galenica Gruppe hat 2013 den konsolidierten Nettoumsatz um 2.0% auf CHF 3'359.4 Mio. gesteigert, dies in einem Markt…